Bayer’s Early R&D And Animal Health To Get Boost After Material Sciences Sell-Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s diversified big pharma company will be getting a bit more focused, with the goal of aiding its faster growing segments.